$0.53
(Market cap
$1,989 Mln
Revenue (TTM)
$98 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7
-
Face value
--
-
Shares outstanding
59,701,882
10 Years Aggregate
CFO
$-2,361.63 Mln
EBITDA
$-3,057.53 Mln
Net Profit
$-584.16 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Agios Pharm (AGIO)
| 25.7 | 14.0 | 16.4 | -9.3 | 7.6 | -5.2 | -0.7 |
|
BSE Sensex*
| -9.8 | -2.2 | 2.8 | -5.0 | 5.3 | 5.9 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Agios Pharm (AGIO)
| -17.2 | 47.1 | -20.7 | -14.6 | -24.1 | -9.3 | 3.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Agios Pharm (AGIO)
|
34.2 | 1,989.3 | 98.3 | -411.3 | -429.3 | -37.1 | -- | 2.0 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Agios Pharm (AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase... (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Read more
-
CEO & Director
Mr. Brian M. Goff M.B.A.
-
CEO & Director
Mr. Brian M. Goff M.B.A.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Agios Pharm (AGIO)
What is the current share price of Agios Pharm (AGIO) Today?
The share price of Agios Pharm (AGIO) is $34.21 (NASDAQ) as of 01-Sep-2026 16:06 EDT. Agios Pharm (AGIO) has given a return of 7.64% in the last 3 years.
What is the current PB & PE ratio of Agios Pharm (AGIO)?
Since, TTM earnings of Agios Pharm (AGIO) is negative, P/E ratio is not available.
The P/B ratio of Agios Pharm (AGIO) is 1.99 times as on 28-Aug-2026, a 62 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.85 |
1.33 |
2024 |
2.79 |
1.22 |
2023 |
-3.54 |
1.53 |
2022 |
-6.64 |
1.40 |
2021 |
1.11 |
1.38 |
What is the 52 Week High and Low of Agios Pharm (AGIO)?
The 52-week high and low of Agios Pharm (AGIO) are Rs 46.00 and Rs 22.24 as of 02-Sep-2026.
What is the market cap of Agios Pharm (AGIO)?
Agios Pharm (AGIO) has a market capitalisation of $ 1,989 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Agios Pharm (AGIO)?
Before investing in Agios Pharm (AGIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.